Crossmark

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?

Crossref DOI link: https://doi.org/10.1007/s11864-022-01020-9

Published Online: 2022-10-13

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beitinjaneh, Amer https://orcid.org/0000-0002-1661-5865
Kaufman, Adrienne

Wang, Yucai

Jain, Preetesh

Srour, Samer A

Wang, Michael
License Information

Text and Data Mining valid from 2022-10-13

Version of Record valid from 2022-10-13
More Information

Article History

Accepted: 20 August 2022

First Online: 13 October 2022

Compliance with Ethical Standards

:

: Amer Beitinjaneh: Research funding (to institution): ATARA, Kite, Tessa, Autolus; Advisory board: Kite. Adrienne Kaufman declares that she has no conflict of interest. Yucai Wang: Research funding (to institution): Incyte, InnoCare, LOXO Oncology, Novartis, Genentech, MorphoSys; Advisory board (compensation to institution): Eli Lilly, TG Therapeutics, LOXO Oncology, Incyte, InnoCare, Kite. Preetesh Jain: Advisory Board: Eli Lilly, Kite, LOXO Oncology, Incyte; Honorarium: Aptitude Health, Pharmacy times; Research Funding—Astra Zeneca, Kite, Beigene. Samer Srour declares that he has no conflict of interest. Michael Wang has received research funding from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Molecular Templates, Oncternal Therapeutics, Pharmacyclics, VelosBio, Vincerx, Celgene, and Genmab; has received compensation for service as a consultant from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, DTRM Biopharma (Cayman) Ltd., Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Oncternal Therapeutics, Pharmacyclics, VelosBio, AbbVie, ADC Therapeutics America, Be Biopharma, Deciphera, Leukemia & Lymphoma Society, Eli Lilly & Co., Merck, Milken Institute, Parexel, and PeproMene Bio; and has received honoraria from Acerta Pharma, AstraZeneca, Anticancer Association, BeiGene, BioInvent, Janssen, Kite Pharma, Pharmacyclics, Physicians Education Resources (PER), AbbVie, Leukemia & Lymphoma Society, Bantam Pharmaceutical, DAVA Oncology, Eastern Virginia Medical School, IDEOlogy Health, TS Oncology, Medscape, Meeting Minds Experts, MD Education, MJH Life Sciences, Moffitt Cancer Center, Oncology Specialty Group, OncLive, Practice Point Communications, and Studio ER Congressi.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current

Any future updates will be listed below